CN110325860A - 方法、阵列和其用途 - Google Patents
方法、阵列和其用途 Download PDFInfo
- Publication number
- CN110325860A CN110325860A CN201880009309.3A CN201880009309A CN110325860A CN 110325860 A CN110325860 A CN 110325860A CN 201880009309 A CN201880009309 A CN 201880009309A CN 110325860 A CN110325860 A CN 110325860A
- Authority
- CN
- China
- Prior art keywords
- weeks
- cancer
- biomarkers
- pancreas
- array
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1701572.8A GB201701572D0 (en) | 2017-01-31 | 2017-01-31 | Methods, arrays and uses thereof |
| GB1701572.8 | 2017-01-31 | ||
| PCT/EP2018/052423 WO2018141804A1 (en) | 2017-01-31 | 2018-01-31 | Methods, arrays and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110325860A true CN110325860A (zh) | 2019-10-11 |
Family
ID=58462729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880009309.3A Pending CN110325860A (zh) | 2017-01-31 | 2018-01-31 | 方法、阵列和其用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190382849A1 (enExample) |
| EP (1) | EP3577464A1 (enExample) |
| JP (1) | JP2020507760A (enExample) |
| KR (1) | KR20190109422A (enExample) |
| CN (1) | CN110325860A (enExample) |
| AU (1) | AU2018214180A1 (enExample) |
| BR (1) | BR112019015633A2 (enExample) |
| CA (1) | CA3051968A1 (enExample) |
| GB (1) | GB201701572D0 (enExample) |
| IL (1) | IL268244A (enExample) |
| MX (1) | MX2019008911A (enExample) |
| RU (1) | RU2019123695A (enExample) |
| WO (1) | WO2018141804A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336851A (zh) * | 2021-06-30 | 2021-09-03 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
| CN120177800A (zh) * | 2025-05-23 | 2025-06-20 | 四川大学 | 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008117067A2 (en) * | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| US12441802B2 (en) | 2019-07-03 | 2025-10-14 | Crystal Bioscience Inc. | Anti-B7-H3 antibody and methods of use thereof |
| KR102289278B1 (ko) * | 2019-07-09 | 2021-08-13 | 주식회사 베르티스 | 췌장암 진단용 바이오마커 패널 및 그 용도 |
| EP4076503A4 (en) * | 2019-12-20 | 2024-04-03 | MedImmune, LLC | Compositions and methods of treating cancer with chimeric antigen receptors targeting glypican 3 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CA3214598A1 (en) * | 2021-03-26 | 2022-09-29 | BioNTech SE | Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013153524A1 (en) * | 2012-04-10 | 2013-10-17 | Immunovia Ab | Methods for determining a breast cancer-associated disease state and arrays for use in the methods |
| CN105917230A (zh) * | 2013-11-11 | 2016-08-31 | 伊缪诺维亚公司 | 用于确定胰腺癌的方法、阵列和其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US8632983B2 (en) * | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| CN106706914B (zh) * | 2010-09-09 | 2018-10-19 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及单克隆抗体 |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
-
2017
- 2017-01-31 GB GBGB1701572.8A patent/GB201701572D0/en not_active Ceased
-
2018
- 2018-01-31 MX MX2019008911A patent/MX2019008911A/es unknown
- 2018-01-31 US US16/479,064 patent/US20190382849A1/en not_active Abandoned
- 2018-01-31 CN CN201880009309.3A patent/CN110325860A/zh active Pending
- 2018-01-31 KR KR1020197022175A patent/KR20190109422A/ko not_active Ceased
- 2018-01-31 RU RU2019123695A patent/RU2019123695A/ru not_active Application Discontinuation
- 2018-01-31 JP JP2019541330A patent/JP2020507760A/ja active Pending
- 2018-01-31 EP EP18703545.6A patent/EP3577464A1/en not_active Withdrawn
- 2018-01-31 CA CA3051968A patent/CA3051968A1/en not_active Abandoned
- 2018-01-31 BR BR112019015633-0A patent/BR112019015633A2/pt not_active Application Discontinuation
- 2018-01-31 AU AU2018214180A patent/AU2018214180A1/en not_active Abandoned
- 2018-01-31 WO PCT/EP2018/052423 patent/WO2018141804A1/en not_active Ceased
-
2019
- 2019-07-24 IL IL268244A patent/IL268244A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013153524A1 (en) * | 2012-04-10 | 2013-10-17 | Immunovia Ab | Methods for determining a breast cancer-associated disease state and arrays for use in the methods |
| CN105917230A (zh) * | 2013-11-11 | 2016-08-31 | 伊缪诺维亚公司 | 用于确定胰腺癌的方法、阵列和其用途 |
| US20160252513A1 (en) * | 2013-11-11 | 2016-09-01 | Immunovia Ab | Method, array and use thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336851A (zh) * | 2021-06-30 | 2021-09-03 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
| CN113336851B (zh) * | 2021-06-30 | 2021-12-24 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
| CN120177800A (zh) * | 2025-05-23 | 2025-06-20 | 四川大学 | 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL268244A (en) | 2019-09-26 |
| RU2019123695A (ru) | 2021-03-02 |
| EP3577464A1 (en) | 2019-12-11 |
| JP2020507760A (ja) | 2020-03-12 |
| CA3051968A1 (en) | 2018-08-09 |
| AU2018214180A1 (en) | 2019-08-08 |
| KR20190109422A (ko) | 2019-09-25 |
| US20190382849A1 (en) | 2019-12-19 |
| GB201701572D0 (en) | 2017-03-15 |
| BR112019015633A2 (pt) | 2020-03-17 |
| MX2019008911A (es) | 2019-09-26 |
| WO2018141804A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mellby et al. | Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer | |
| CN110325860A (zh) | 方法、阵列和其用途 | |
| JP6161542B2 (ja) | 方法、アレイ及びその使用 | |
| US20220206004A1 (en) | Method, array and use thereof | |
| EP3353552B1 (en) | Method and array for diagnosing pancreatic cancer in an individual | |
| ES2704888T3 (es) | Método, matriz y uso de los mismos para determinar cáncer de páncreas | |
| US20070292869A1 (en) | Compositions and Methods for Analyzing Renal Cancer | |
| KR20160045547A (ko) | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 | |
| US20220026431A1 (en) | Methods, arrays and uses thereof | |
| JP6674889B2 (ja) | 前立腺がんに対するバイオマーカー検出における使用のための方法とアレイ | |
| US20170192004A1 (en) | Methods and Arrays for Use in the Same | |
| US20070264643A1 (en) | Compositions and Methods Relating to CNS Lymphoma | |
| Kafle et al. | Current state of knowledge on blood and tissue-based biomarkers for opisthorchis viverrini-induced Cholangiocarcinoma: a review of prognostic, predictive, and diagnostic markers | |
| US20230213521A1 (en) | Biomarkers for detection of lung cancer | |
| CN115372616A (zh) | 胃癌相关的生物标志物及其应用 | |
| WO2015092075A1 (en) | Cers5 as a predictive variable of response to cancer therapy and in particular neoadjuvant cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191011 |
|
| WD01 | Invention patent application deemed withdrawn after publication |